Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un ensayo de fase 3 para evaluar CYB003 en el trastorno depresivo mayor (EMBRACE)

12 de noviembre de 2026 actualizado por: Cybin IRL Limited

Un estudio controlado aleatorizado de eficacia y seguridad, fase III, múltiples centros, doble ciego, que comparan 2 dosis activas de CyB003 y placebo en participantes elegibles con trastorno depresivo mayor

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

330

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Berlin, Alemania, 10117
        • Aún no reclutando
        • Charité Universitaetsmedizin Berlin
        • Investigador principal:
          • Michael Koslowski
        • Contacto:
      • Frankfurt am Main, Alemania, 60528
        • Aún no reclutando
        • University Hospital Frankfurt
        • Investigador principal:
          • Andreas Reif
        • Contacto:
      • Mannheim, Alemania, 68159
        • Aún no reclutando
        • Central Institute of Mental Health
        • Contacto:
        • Investigador principal:
          • Gerhard Grüender
    • Saarland
      • Homburg, Saarland, Alemania, 66421
        • Aún no reclutando
        • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
        • Investigador principal:
          • Matthias Riemenschneider
        • Contacto:
        • Contacto:
          • Aline Freer
          • Número de teléfono: +49 6841 1614219
          • Correo electrónico: aline.freer@uks.eu
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Reclutamiento
        • Royal Prince Alfred Hospital
        • Investigador principal:
          • Nicholas Glozier
    • Queensland
      • Maroochydore, Queensland, Australia, 4558
        • Reclutamiento
        • Thompson Brain & Mind Healthcare (TBMH)
        • Investigador principal:
          • Adem Can
        • Contacto:
        • Contacto:
          • Kristy Smyth
          • Número de teléfono: +61 4324 41227
          • Correo electrónico: ksmyth@tbmh.org.au
    • Victoria
      • Melbourne, Victoria, Australia, 3004
      • Melbourne, Victoria, Australia, 3053
        • Reclutamiento
        • Neurocentrix Research
        • Investigador principal:
          • David Barton
        • Contacto:
        • Contacto:
      • Notting Hill, Victoria, Australia, 3168
        • Reclutamiento
        • Monash University - Notting Hill
        • Contacto:
        • Investigador principal:
          • Paul Liknaitzky
      • Prague, Chequia
        • Aún no reclutando
        • Institute of neuropsychiatric Care (INEP)
        • Investigador principal:
          • Alexander Nawka
        • Contacto:
          • Número de teléfono: +420 222 201 020
          • Correo electrónico: info@inep.cz
      • Prague, Chequia
        • Aún no reclutando
        • Psyon s.r.o.
        • Investigador principal:
          • Tomas Palenicek
        • Contacto:
          • Número de teléfono: +420 774 401 161
          • Correo electrónico: info@psyon.cz
      • Předměstí, Chequia
        • Aún no reclutando
        • A-SHINE s.r.o.
        • Investigador principal:
          • Lubos Janu
        • Contacto:
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35209
        • Reclutamiento
        • UAB Psychiatry and Behavioral Neurology
        • Contacto:
          • Seher Premani
          • Número de teléfono: 205-996-1198
          • Correo electrónico: spremani@uab.edu
        • Investigador principal:
          • Peter Hendricks
        • Contacto:
    • Arizona
      • Gilbert, Arizona, Estados Unidos, 85234
        • Reclutamiento
        • Lighthouse Psychiatry
        • Contacto:
        • Investigador principal:
          • Frank Genova
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72204
        • Retirado
        • Pillar Clinical Research - Little Rock
    • California
      • Glendale, California, Estados Unidos, 91206
        • Reclutamiento
        • Behavioral Research Specialists, LLC
        • Investigador principal:
          • Jesse Carr
        • Contacto:
      • Imperial, California, Estados Unidos, 92251
        • Retirado
        • Sun Valley Research Center
      • Los Angeles, California, Estados Unidos, 90025
        • Reclutamiento
        • CalNeuro Research Group
        • Investigador principal:
          • Alexander Bystritsky
        • Contacto:
      • Los Angeles, California, Estados Unidos, 90025
        • Reclutamiento
        • Lipov Medical Group
        • Contacto:
        • Investigador principal:
          • Jacob Moussai
      • Orange, California, Estados Unidos, 92868
        • Reclutamiento
        • NRC Research Institute
        • Contacto:
        • Investigador principal:
          • Daniel Chueh
      • Orange, California, Estados Unidos, 92866
        • Reclutamiento
        • ATP Clinical Research
        • Investigador principal:
          • Gustavo Alva
        • Contacto:
          • Sarah Perkins
          • Número de teléfono: 949-354-5353
          • Correo electrónico: sarahp@pnsoc.com
      • San Juan Capistrano, California, Estados Unidos, 92675
        • Reclutamiento
        • Inland Psychiatric Medical Group Inc (IPMG Research)
        • Investigador principal:
          • Neelima Kunam
        • Contacto:
      • Santa Monica, California, Estados Unidos, 90404
        • Reclutamiento
        • Psychedelic Science Institute
        • Investigador principal:
          • Keith Heinzerling
        • Contacto:
      • Stanford, California, Estados Unidos, 94305
        • Retirado
        • Stanford University
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06511
        • Reclutamiento
        • Yale School of Medicine - Yale Program for Psychedelic Science
        • Investigador principal:
          • Ben Kelmendi
        • Contacto:
          • Daidre Chamberlain
          • Número de teléfono: 203-693-1591
          • Correo electrónico: enact@yale.edu
        • Contacto:
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32256
        • Reclutamiento
        • CNS Healthcare
        • Contacto:
          • Número de teléfono: 904-281-5757
        • Investigador principal:
          • John Mark Joyce
      • Maitland, Florida, Estados Unidos, 32751
        • Reclutamiento
        • Accel Research Sites - Maitland
        • Contacto:
          • Número de teléfono: 407-644-1165
        • Investigador principal:
          • Andrea Marrafino
      • Naples, Florida, Estados Unidos, 34105
        • Reclutamiento
        • Aqualane Clinical Research
        • Investigador principal:
          • Matthew Baker
        • Contacto:
      • Tampa, Florida, Estados Unidos, 33634
        • Reclutamiento
        • K2 Medical Research Tampa
        • Investigador principal:
          • Kelley Wilson
        • Contacto:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30329
        • Retirado
        • Emory University Dept of Psychiatry and Behavioral Studies
      • Marietta, Georgia, Estados Unidos, 30060
        • Reclutamiento
        • Psych Atlanta
        • Investigador principal:
          • Michael Banov
        • Contacto:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Reclutamiento
        • Rush University
        • Investigador principal:
          • Joshua Eloge
        • Contacto:
    • Louisiana
      • Marrero, Louisiana, Estados Unidos, 70006
        • Retirado
        • Tandem Clinical Research
      • New Orleans, Louisiana, Estados Unidos, 70115
        • Reclutamiento
        • Atlas Psychiatry
        • Contacto:
        • Investigador principal:
          • Nicholas Pejic
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21224
        • Retirado
        • Johns Hopkins Medicine
      • Rockville, Maryland, Estados Unidos, 20850
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02116
        • Reclutamiento
        • Adams Clinical Boston
        • Investigador principal:
          • Darin Dougherty
        • Contacto:
      • Watertown, Massachusetts, Estados Unidos, 02472
        • Reclutamiento
        • Adams Clinical Watertown
        • Investigador principal:
          • Stephanie Ellickson
        • Contacto:
    • Minnesota
      • Eden Prairie, Minnesota, Estados Unidos, 55347
        • Reclutamiento
        • Institute for Integrative Therapies
        • Investigador principal:
          • Manoj Doss
        • Contacto:
      • Golden Valley, Minnesota, Estados Unidos, 55427
        • Aún no reclutando
        • The Remedy Mental Health
        • Contacto:
        • Investigador principal:
          • Wayne Bentham
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89119
        • Reclutamiento
        • Redbird Research, LLC
        • Investigador principal:
          • Jelena Kunovac
        • Contacto:
    • New Jersey
      • Toms River, New Jersey, Estados Unidos, 08755
        • Reclutamiento
        • Bio Behavioral Health
        • Contacto:
          • Jessica Sutton
          • Número de teléfono: 732-244-2299
          • Correo electrónico: jessica@bbhnj.com
        • Investigador principal:
          • Ashok Patel
    • New York
      • New York, New York, Estados Unidos, 10032
        • Aún no reclutando
        • New York State Psychiatric Institute
        • Investigador principal:
          • Natalie Gukasyan
        • Contacto:
      • New York, New York, Estados Unidos, 10029
        • Reclutamiento
        • Adams Clinical Harlem
        • Contacto:
        • Investigador principal:
          • Wesley Gregory
      • The Bronx, New York, Estados Unidos, 10461
        • Reclutamiento
        • Adams Clinical Bronx
        • Investigador principal:
          • Shama Farooq
        • Contacto:
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73112
        • Retirado
        • SP Research PLLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Reclutamiento
        • Adams Clinical Philadelphia
        • Investigador principal:
          • Cassie Blanchard
        • Contacto:
      • Philadelphia, Pennsylvania, Estados Unidos, 19462
        • Reclutamiento
        • Flourish Research Philadelphia
        • Investigador principal:
          • Rachna Saralkar
        • Contacto:
          • Número de teléfono: 215-614-5606
    • Texas
      • Austin, Texas, Estados Unidos, 78737
        • Retirado
        • Austin Clinical Trial Partners
      • DeSoto, Texas, Estados Unidos, 75115
        • Reclutamiento
        • Adams Clinical Dallas
        • Investigador principal:
          • Rajinder Shiwach
        • Contacto:
      • Fort Worth, Texas, Estados Unidos, 76104
        • Retirado
        • North Texas Clinical Trials
      • Houston, Texas, Estados Unidos, 77046
        • Reclutamiento
        • Brain Health Consultants and TMS Center
        • Investigador principal:
          • Lauren Marangell
        • Contacto:
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • Flourish Research San Antonio
        • Investigador principal:
          • Parke Hedges
        • Contacto:
        • Contacto:
    • Washington
      • Everett, Washington, Estados Unidos, 98201
        • Aún no reclutando
        • Core Clinical Research
        • Contacto:
        • Investigador principal:
          • James Knutson
      • Seattle, Washington, Estados Unidos, 98104
        • Reclutamiento
        • Seattle Neuropsychiatric Treatment Center
        • Investigador principal:
          • Rebecca Allen
        • Contacto:
      • Athens, Grecia, 12462
        • Reclutamiento
        • Attikon University Hospital
        • Investigador principal:
          • Nikolaos Smyrnis
        • Contacto:
      • Athens, Grecia, 11528
        • Reclutamiento
        • Eginitio Hospital
        • Investigador principal:
          • Nikos Stefanis
        • Contacto:
      • Thessaloniki, Grecia, 56404
        • Reclutamiento
        • Papageorgiou General Hospital
        • Investigador principal:
          • Georgios Papazisis
        • Contacto:
      • Dublin, Irlanda, D24 WK80
        • Reclutamiento
        • Sheaf House - Tallaght Adult Mental Health Service
        • Investigador principal:
          • John Kelly
        • Contacto:
      • Galway, Irlanda, H91 VE03
        • Reclutamiento
        • La Nua Day Hospital Mental Health Centre
        • Contacto:
        • Investigador principal:
          • Shane McInerney
      • Bialystok, Polonia, 15-272
        • Retirado
        • Uniwersytecki Szpital Kliniczny W Białymstoku
      • Bydgoszcz, Polonia, 85-133
        • Reclutamiento
        • Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
        • Contacto:
        • Investigador principal:
          • Katarzyna Lachut
      • Gdansk, Polonia, 80-546
        • Reclutamiento
        • Centrum Badan Klinicznych PI-House Sp. z o.o
        • Contacto:
        • Investigador principal:
          • Hanna Badzio-Jagiello
      • Gdansk, Polonia, 80-214
        • Aún no reclutando
        • UCK
        • Investigador principal:
          • Wieslaw Jerzy Cubala
        • Contacto:
      • Warsaw, Polonia, 02-957
        • Aún no reclutando
        • Department of Pharmacology and Physiology of CNS
        • Investigador principal:
          • Justyna Holka-Pokorska
      • Warsaw, Polonia, 02-172
        • Reclutamiento
        • MTZ Clinical Research Powered by Pratia
        • Investigador principal:
          • Monika Gawlowicz
      • Cambridge, Reino Unido, CB1 2EU
        • Reclutamiento
        • Cambridge University Hospital NHS
        • Investigador principal:
          • Liliana Galindo
        • Contacto:
          • Tracy Assari
          • Número de teléfono: +44 1223 219751
          • Correo electrónico: t.assari@nhs.net
        • Contacto:
      • Doncaster, Reino Unido, DN4 8QN
        • Reclutamiento
        • Clerkenwell Health - Doncaster
        • Investigador principal:
          • Paul Morrison
        • Contacto:
      • Edinburgh, Reino Unido, EH16 4TJ
        • Aún no reclutando
        • NHS Research Scotland
        • Investigador principal:
          • Donald MacIntyre
        • Contacto:
      • Glasgow, Reino Unido, G51 4TF
        • Aún no reclutando
        • Queen Elizabeth University Hospital
        • Investigador principal:
          • Maytal Wolfe
        • Contacto:
      • Liverpool, Reino Unido, L7 8XP
        • Aún no reclutando
        • Royal Liverpool Hospital
        • Contacto:
        • Investigador principal:
          • Fabian Devlin
      • London, Reino Unido, EC2Y 8EA
        • Reclutamiento
        • St Pancras Clinical Research
        • Investigador principal:
          • Martin Johnson
        • Contacto:
      • London, Reino Unido, W1U 6RP
        • Reclutamiento
        • Clerkenwell Health - Baker Street
        • Investigador principal:
          • Alishah Suleman
        • Contacto:
        • Contacto:
      • London, Reino Unido, W1G9 RU
        • Reclutamiento
        • Re:Cognition Health
        • Investigador principal:
          • Dimitrios Paschos
        • Contacto:
          • Número de teléfono: +44-0800-802-1030
      • London, Reino Unido, SE5 9RS
      • London, Reino Unido, W1G 8DR
        • Retirado
        • Clerkenwell Health - Welbeck Street
      • Newcastle upon Tyne, Reino Unido, NE4 5PL
        • Reclutamiento
        • Edwardson Building - Campus for Ageing and Vitality
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Mourad Wahba
      • Reading, Reino Unido, RG7 8PA
        • Reclutamiento
        • Ascend Clinical Research
        • Investigador principal:
          • Pamela Walters
        • Contacto:
      • Sheffield, Reino Unido, S4 7QQ
        • Reclutamiento
        • Sheffield Health and Social Care NHS Foundation Trust
        • Investigador principal:
          • William Gann
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Age18 to 85 years.
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Moderate to severe depression at Screening and Baseline, independently confirmed.
  • Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
  • Participants have a presence or relevant history of organic brain disorders.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
  • Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Experimental: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Comparador de placebos: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Manualized psychological support performed by facilitator.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Montgomery-Asberg Depression Scale (MADRS)
Periodo de tiempo: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity.

The total score ranges 0-60, higher scores denote greater severity.

Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The Beck Depression Inventory - Second Edition (BDI-II)
Periodo de tiempo: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.

Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0.

Day -1, Day 21, Day 42 and Day 84/End of Trial.
The Clinical Global Impression Scale (CGI-S)
Periodo de tiempo: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.

The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index.

Only the severity of illness ang global improvement measures will be utilized for this trial.

Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:

  1. = Normal, not at all ill
  2. = Borderline ill
  3. = Mildly ill
  4. = Moderately ill
  5. = Markedly ill
  6. = Severely ill
  7. = Among the most extremely ill patients
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Periodo de tiempo: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms.

Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows:

Scores represent:

0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety

Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Periodo de tiempo: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities.

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.

Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70

Day -1, Day 21, Day 42 and Day 84/End of Trial.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Felix Mazer, Cybin IRL Limited

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de diciembre de 2025

Finalización primaria (Estimado)

7 de junio de 2027

Finalización del estudio (Estimado)

9 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de enero de 2025

Primero enviado que cumplió con los criterios de control de calidad

21 de enero de 2025

Publicado por primera vez (Actual)

27 de enero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir